{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:46:12Z","timestamp":1790707572587,"version":"4.1.0"},"reference-count":37,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.2967\/jnumed.121.262671","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T13:20:56Z","timestamp":1631798456000},"page":"833-839","source":"Crossref","is-referenced-by-count":32,"title":["Pretherapeutic Comparative Dosimetry of<sup>177<\/sup>Lu-rhPSMA-7.3 and<sup>177<\/sup>Lu-PSMA I&amp;T in Patients with Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.2967","volume":"63","author":[{"given":"Benedikt","family":"Feuerecker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maythinee","family":"Chantadisai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Allmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Tauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Allmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Steinhelfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Rauscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Wurzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-J\u00fcrgen","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang A.","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Calogero","family":"d\u2019Alessandria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Eiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"2025012107351094000_63.6.833.1","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.7150\/thno.13348","article-title":"PSMA ligands for radionuclide imaging and therapy of prostate cancer: clinical status","volume":"5","author":"L\u00fctje","year":"2015","journal-title":"Theranostics."},{"key":"2025012107351094000_63.6.833.2","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2018.11.016","article-title":"Treatment outcome, toxicity, and predictive factors for radioligand therapy with 177Lu-PSMA-I&T in metastatic castration-resistant prostate cancer","volume":"75","author":"Heck","year":"2019","journal-title":"Eur Urol."},{"key":"2025012107351094000_63.6.833.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30198-0"},{"key":"2025012107351094000_63.6.833.4","doi-asserted-by":"crossref","unstructured":"Morris MJ De Bono JS Chi KN . Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION) [abstract LBA4]. J Clin Oncol. 2021;39(suppl).","DOI":"10.1200\/JCO.2021.39.15_suppl.LBA4"},{"key":"2025012107351094000_63.6.833.5","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.178483"},{"key":"2025012107351094000_63.6.833.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3125-3"},{"key":"2025012107351094000_63.6.833.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.171397"},{"key":"2025012107351094000_63.6.833.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-015-3174-7"},{"key":"2025012107351094000_63.6.833.9","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-016-0942-0"},{"key":"2025012107351094000_63.6.833.10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4274\/mirt.08760","article-title":"Lu-177-PSMA-617 prostate-specific membrane antigen inhibitor therapy in patients with castration-resistant prostate cancer: stability, bio-distribution and dosimetry","volume":"26","author":"Kabasakal","year":"2017","journal-title":"Mol Imaging Radionucl Ther."},{"key":"2025012107351094000_63.6.833.11","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234914"},{"key":"2025012107351094000_63.6.833.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234906"},{"key":"2025012107351094000_63.6.833.13","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234609"},{"key":"2025012107351094000_63.6.833.14","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.234922"},{"key":"2025012107351094000_63.6.833.15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13550-020-00740-z","article-title":"Preclinical comparison of four [18F, (nat)Ga]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics","volume":"10","author":"Wurzer","year":"2020","journal-title":"EJNMMI Res."},{"key":"2025012107351094000_63.6.833.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.254516"},{"key":"2025012107351094000_63.6.833.17","doi-asserted-by":"publisher","DOI":"10.4329\/wjr.v7.i8.202"},{"key":"2025012107351094000_63.6.833.18","first-page":"37S","article-title":"MIRD Pamphlet No. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates","volume":"40","author":"Siegel","year":"1999","journal-title":"J Nucl Med."},{"key":"2025012107351094000_63.6.833.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-010-1422-4"},{"key":"2025012107351094000_63.6.833.20","first-page":"1023","article-title":"OLINDA\/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine","volume":"46","author":"Stabin","year":"2005","journal-title":"J Nucl Med."},{"key":"2025012107351094000_63.6.833.21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cpet.2013.08.014","article-title":"Relevance of PET for pretherapeutic prediction of doses in peptide receptor radionuclide therapy","volume":"9","author":"Blaickner","year":"2014","journal-title":"PET Clin."},{"key":"2025012107351094000_63.6.833.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2016.02.2969"},{"key":"2025012107351094000_63.6.833.23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2020.05.004","article-title":"Efficacy and safety of 177Lu-labeled prostate-specific membrane antigen radionuclide treatment in patients with diffuse bone marrow involvement: a multicenter retrospective study","volume":"78","author":"Gafita","year":"2020","journal-title":"Eur Urol."},{"key":"2025012107351094000_63.6.833.24","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1053\/j.semnuclmed.2019.02.008","article-title":"PSMA-targeted radiopharmaceuticals for imaging and therapy","volume":"49","author":"Wester","year":"2019","journal-title":"Semin Nucl Med."},{"key":"2025012107351094000_63.6.833.25","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(91)90171-Y"},{"key":"2025012107351094000_63.6.833.26","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/ckj\/sfz101","article-title":"Renal outcomes of radioligand therapy: experience of 177lutetium\u2013prostate-specific membrane antigen ligand therapy in metastatic castrate-resistant prostate cancer","volume":"13","author":"Gallyamov","year":"2019","journal-title":"Clin Kidney J."},{"key":"2025012107351094000_63.6.833.27","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2005.20.47"},{"key":"2025012107351094000_63.6.833.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-008-0778-1"},{"key":"2025012107351094000_63.6.833.29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1026"},{"key":"2025012107351094000_63.6.833.30","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.18632\/oncotarget.12240","article-title":"Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer","volume":"8","author":"Fendler","year":"2017","journal-title":"Oncotarget."},{"key":"2025012107351094000_63.6.833.31","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s00259-016-3609-9","article-title":"The 68Ga\/177Lu theragnostic concept in PSMA targeting of castration-resistant prostate cancer: correlation of SUVmax values and absorbed dose estimates","volume":"44","author":"Scarpa","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025012107351094000_63.6.833.32","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.219352"},{"key":"2025012107351094000_63.6.833.33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.115.168443"},{"key":"2025012107351094000_63.6.833.34","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025012107351094000_63.6.833.35","doi-asserted-by":"crossref","unstructured":"Tagawa ST Niaz MJ Osborne J . Phase I\/II dose-escalation trial of fractionated dose 177Lu-J591 plus 177Lu-PSMA-617 for metastatic castration-resistant prostate cancer (mCRPC) [abstract TPS339]. J Clin Oncol. 2019;37 (suppl).","DOI":"10.1200\/JCO.2019.37.7_suppl.TPS339"},{"key":"2025012107351094000_63.6.833.36","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/1874471008666150312160855","article-title":"Production of no-carrier added lutetium-177 by irradiation of enriched ytterbium-176","volume":"8","author":"Tarasov","year":"2015","journal-title":"Curr Radiopharm."},{"key":"2025012107351094000_63.6.833.37","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2298-2"}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.121.262671","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T16:03:05Z","timestamp":1737475385000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.121.262671"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,1]]},"published-print":{"date-parts":[[2022,6]]}},"alternative-id":["10.2967\/jnumed.121.262671"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.121.262671","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]}}}